Pharvaris (NASDAQ:PHVS) Director Sells 11,969 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 11,969 shares of the company’s stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total transaction of $395,575.45. Following the completion of the sale, the director directly owned 5,500 shares of the company’s stock, valued at approximately $181,775. This represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Pharvaris Price Performance

Shares of Pharvaris stock traded down $0.78 on Friday, hitting $32.22. The company had a trading volume of 271,150 shares, compared to its average volume of 417,060. Pharvaris N.V. has a 52 week low of $20.65 and a 52 week high of $43.25. The company has a market cap of $2.11 billion, a PE ratio of -10.58 and a beta of -2.33. The business has a 50-day simple moving average of $35.35 and a 200-day simple moving average of $31.98.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities research analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PHVS shares. Morgan Stanley boosted their price target on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Guggenheim raised their price objective on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Citizens Jmp lifted their price objective on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday, September 9th. UBS Group set a $79.00 target price on shares of Pharvaris in a report on Wednesday, September 9th. Finally, Royal Bank Of Canada increased their target price on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PHVS. Quantbot Technologies LP acquired a new stake in Pharvaris in the 2nd quarter worth approximately $41,000. CoreCap Advisors LLC bought a new position in shares of Pharvaris in the second quarter valued at approximately $93,000. Amundi lifted its stake in shares of Pharvaris by 12.0% in the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after buying an additional 3,312 shares during the last quarter. Sofinnova Investments Inc. boosted its holdings in shares of Pharvaris by 0.7% during the 4th quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company’s stock worth $20,678,000 after buying an additional 5,293 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in Pharvaris in the 2nd quarter valued at $196,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.